ArticleScientific reports2026
Differences in composition and diversity of the gut microbiota of post-menopausal breast cancer patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota colonizes the intestinal tract with essential roles in immune function, gut epithelial integrity, and metabolic signaling. To investigate the relationship between microbiota composition and breast cancer development, stool samples were collected from 27 treatment naïve post-menopausal breast cancer patients of varying hormone receptor statuses and 25 post-menopausal participants without breast cancer who served as controls. Samples from breast cancer patients and controls were compared for significant differences (p<0.05) in alpha and beta diversity. Significant differences in alpha diversity were observed between all breast cancer types compared to controls (padj=0.042), and between ER+Her2- breast cancer compared to controls (padj=0.006). Using principal coordinate analyses (PCA), significant differences in beta diversity were identified between all breast cancer types compared to controls (padj=0.048), and ER+Her2- breast cancer compared to controls (padj=0.036). Further analyses identified key microbiota genera of microbiota related to breast cancer development and progression. Notably, Akkermansia, a genus associated with gut barrier dysfunction, was reduced in ER+Her2- patients. Overall, this study reports on alterations in microbiota composition in stool samples from untreated postmenopausal breast cancer patients compared to control subjects. The data obtained could provide important insights into the association between altered microbiota and breast cancer progression and guide future patient screening and prevention efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.